Skip to main content
SpringerLink
Log in

Dabigatran etexilate

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Credit: Dabigatran etexilate

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous thromboembolic events in patients who have undergone total hip- or knee-replacement surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Anticoagulant drugs.

References

  1. Mackman, N. Triggers, targets and treatments for thrombosis. Nature 451, 914–918 (2008).

    Article  CAS  Google Scholar 

  2. Geerts, W. H. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 338S–400S (2004).

    Article  CAS  Google Scholar 

  3. Di Nisio, M. et al. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028–1040 (2005).

    Article  CAS  Google Scholar 

  4. Hauel, N. H. et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 45, 1757–1766 (2002).

    Article  CAS  Google Scholar 

  5. Wienen, W. et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb. Haemost. 98, 333–338 (2007).

    Article  CAS  Google Scholar 

  6. European Medicines Agency (EMEA). European Public Assessment Report — Pradaxa. EMEA web site [online], (2008).

  7. Eriksson, B. I. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Thromb. Haemost. 5, 2178–2185 (2007).

    Article  CAS  Google Scholar 

  8. Eriksson, B. I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949–956 (2007).

    Article  CAS  Google Scholar 

  9. IMS, MIDAS Quantum (2007).

Download references

Author information

Authors and Affiliations

  1. Bengt I. Eriksson is at the Department of Orthopaedic Surgery, Sahlgrenska University Hospital/Östra, SE-416 85 Gothenburg, Sweden. b.eriksson@orthop.gu.se,

    Bengt I. Eriksson

  2. Helen Smith and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Helen Smith & Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Bengt I. Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

B.I.E. has received consulting fees from Bayer Healthcare, Boehringer Ingelheim and Astellas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eriksson, B., Smith, H., Yasothan, U. et al. Dabigatran etexilate. Nat Rev Drug Discov 7, 557–558 (2008). https://doi.org/10.1038/nrd2622

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2622

  • Springer Nature Limited

This article is cited by

Search

Navigation